Criteo SA (NASDAQ:CRTO)
On its financial results, CRTO delivered another record quarter exceeding its expectations, driven by focused execution across the business in all regions.
For the second quarter 2014, CRTO posted revenue of EURO165.3 million, a 66.3% increase (or 71.5% at constant currency) compared to the same period the prior year, while its net income increased by EURO8.0 million to EURO2.4 million, compared with a net loss of EURO5.6 million in the second quarter 2013.
CRTO is increasing its Adjusted EBITDA outlook for the fiscal year 2014, now expected to be between EURO55.5 million and EURO59.5 million.
CRTO delivers personalized performance advertising at an extensive scale.
Impax Laboratories, Inc. (NASDAQ:IPXL)
Keep a close eye on IPXL. On its financial results, the company delivered strong revenue growth, adjusted gross margins of 64%, and nearly tripled its adjusted net income versus the same period the prior year.
For the second quarter 2014, IPXL posted total revenues of $188.1 million, a 45.1% increase year over year, and adjusted diluted earnings per share of $0.60, compared to $0.23 per diluted share in the prior year period. On a GAAP basis, diluted earnings per share increased to $0.50, compared to $0.08 per diluted share in the second quarter 2013.
IPXL is a technology based specialty pharmaceutical company applying its formulation expertise and drug delivery technology to the development of controlled-release and specialty generics in addition to the development of central nervous system disorder branded products
Read Full Disclaimer at www.finance.crwe-pr.com/disclaimer
Disclosure: The author has no positions in any stocks mentioned, and no plans to initiate any positions within the next 72 hours.